- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00004037
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
Evaluation of Docetaxel in Recurrent, Platinum Resistant, Refractory and Paclitaxel Refractory Ovarian Cancer and Primary Peritoneal Carcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or refractory ovarian or primary peritoneal cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES: I. Estimate the antitumor activity of docetaxel in patients with paclitaxel- and platinum-resistant, recurrent or refractory, ovarian epithelial or primary peritoneal cancer who have failed on higher priority treatment protocols. II. Determine the nature and degree of toxicity of docetaxel in this patient population.
OUTLINE: Patients receive docetaxel as a 1 hour continuous intravenous infusion. Courses are repeated every 21 days. Treatment continues in the absence of unacceptable toxic effects or disease progression. All patients are followed every 3 months for 2 years, every 6 months for 3 years, and then until death.
PROJECTED ACCRUAL: A total of 23-56 patients will be accrued for this study.
Type d'étude
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 3N6
- NCIC-Clinical Trials Group
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006-2726
- CCOP - Greater Phoenix
-
-
California
-
Los Angeles, California, États-Unis, 90033-0800
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, États-Unis, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Orange, California, États-Unis, 92868
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, États-Unis, 94304
- Women's Cancer Center
-
-
Colorado
-
Denver, Colorado, États-Unis, 80262
- University of Colorado Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20307-5000
- Walter Reed Army Medical Center
-
Washington, District of Columbia, États-Unis, 20007
- Vincent T. Lombardi Cancer Research Center, Georgetown University
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory University Hospital - Atlanta
-
Atlanta, Georgia, États-Unis, 30342-1701
- CCOP - Atlanta Regional
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
Chicago, Illinois, États-Unis, 60637
- University of Chicago Cancer Research Center
-
Evanston, Illinois, États-Unis, 60201
- CCOP - Evanston
-
Springfield, Illinois, États-Unis, 62526
- CCOP - Central Illinois
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202-5265
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536-0084
- Albert B. Chandler Medical Center, University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins Oncology Center
-
Bethesda, Maryland, États-Unis, 20892
- Radiation Oncology Branch
-
Bethesda, Maryland, États-Unis, 20892
- Medicine Branch
-
-
Massachusetts
-
Worcester, Massachusetts, États-Unis, 01655
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- CCOP - Ann Arbor Regional
-
Detroit, Michigan, États-Unis, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216-4505
- University of Mississippi Medical Center
-
Keesler AFB, Mississippi, États-Unis, 39534-2576
- Keesler Medical Center - Keesler AFB
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
Montana
-
Billings, Montana, États-Unis, 59101
- CCOP - Montana Cancer Consortium
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68131
- CCOP - Missouri Valley Cancer Consortium
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89106
- CCOP - Southern Nevada Cancer Research Foundation
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Albany, New York, États-Unis, 12208
- Cancer Center of Albany Medical Center
-
Brooklyn, New York, États-Unis, 11203
- State University of New York Health Science Center at Brooklyn
-
Manhasset, New York, États-Unis, 11030
- North Shore University Hospital
-
New York, New York, États-Unis, 10021
- Memorial Sloan-Kettering Cancer Center
-
Rochester, New York, États-Unis, 14642
- University of Rochester Cancer Center
-
Stony Brook, New York, États-Unis, 11790-9832
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, États-Unis, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, États-Unis, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
Winston-Salem, North Carolina, États-Unis, 27103
- Brookview Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- Barrett Cancer Center, The University Hospital
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Cancer Center
-
Cleveland, Ohio, États-Unis, 44106-5065
- Ireland Cancer Center
-
Columbus, Ohio, États-Unis, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73190
- University of Oklahoma College of Medicine
-
Tulsa, Oklahoma, États-Unis, 74136
- CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
-
-
Oregon
-
Portland, Oregon, États-Unis, 97213
- CCOP - Columbia River Program
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, États-Unis, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Pennsylvania Hospital
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania Cancer Center
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425-0721
- Medical University of South Carolina
-
Spartanburg, South Carolina, États-Unis, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38117
- CCOP - Baptist Cancer Institute
-
-
Texas
-
Dallas, Texas, États-Unis, 75235-9154
- Simmons Cancer Center - Dallas
-
Houston, Texas, États-Unis, 77030
- University of Texas - MD Anderson Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Cancer Center, University of Virginia HSC
-
-
Washington
-
Seattle, Washington, États-Unis, 98195-6043
- University of Washington Medical Center
-
Tacoma, Washington, États-Unis, 98405
- Tacoma General Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or refractory ovarian epithelial or peritoneal cancer Platinum resistant AND paclitaxel resistant Progressed on or within 6 months of completing therapy with paclitaxel and platinum either alone or in combination Bidimensionally measurable disease (excludes ascites and pleural effusions) Brain metastases allowed provided that other measurable disease exists and brain lesions required no therapy for 6 months and are not life threatening Not eligible for higher priority GOG protocol
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: At least 8 weeks Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT/SGPT no greater than 1.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: No significant infection Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E) No other invasive malignancies within the past 5 years except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics Must have had at least 1 prior platinum based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound Must have had at least 1 prior paclitaxel based chemotherapeutic regimen 1 or 2 prior chemotherapy regimens containing platinum and paclitaxel allowed Recovered from toxic effects No prior docetaxel Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Recovered from effects of recent surgery Other: At least 3 weeks since any prior therapy directed at the malignant tumor No prior cancer treatment that contraindicates this protocol therapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Peter G. Rose, MD, The Cleveland Clinic
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs urogénitales
- Tumeurs par site
- Carcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs génitales, femme
- Maladies du système endocrinien
- Maladies ovariennes
- Maladies annexielles
- Troubles gonadiques
- Tumeurs des glandes endocrines
- Tumeurs ovariennes
- Carcinome épithélial ovarien
- Mécanismes moléculaires de l'action pharmacologique
- Agents antinéoplasiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Docétaxel
Autres numéros d'identification d'étude
- CDR0000066369
- GOG-126J
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer des ovaires
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
Essais cliniques sur docétaxel
-
Fudan UniversityPas encore de recrutementCancer du poumon non à petites cellules avancé
-
Wake Forest University Health SciencesAstellas Pharma Inc; Medivation, Inc.Actif, ne recrute pasCancer de la prostate | Adénocarcinome de la prostateÉtats-Unis
-
University Hospital, BonnSanofiInconnue
-
Zhao ChongZhejiang Cancer Hospital; Wuhan University; Fudan University; Fujian Cancer Hospital et autres collaborateursComplétéCarcinome du nasopharynx | MalnutritionChine
-
Tianjin Medical University Cancer Institute and...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Pas encore de recrutementCancer du poumon non à petites cellules localement avancé résécableChine
-
Samsung Medical CenterSanofiComplétéCarcinome pulmonaire non à petites cellulesCorée, République de
-
Nicklaus Children's Hospital f/k/a Miami Children...Actif, ne recrute pasOstéosarcome métastatique | Sarcome d'Ewing métastatiqueÉtats-Unis
-
Memorial Sloan Kettering Cancer CenterSanofiComplété
-
Austrian Breast & Colorectal Cancer Study GroupHoffmann-La Roche; CephalonComplété
-
Sun Yat-sen UniversityRecrutementCarcinome du nasopharynxChine